US Pharma MarketingAstraZeneca
AstraZeneca’s Tagrisso-Orpathys combo cuts risk of death 32% vs. chemo in MET-driven, post-Tagrisso NSCLC in Ph3 SAFFRON. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug…
MADRID — AstraZeneca said Sunday it might have found a way for patients with mutant non-small cell lung cancer to keep taking Tagrisso even after they have become resistant to the EGFR-targeting tyrosine kinase inhibitor.
In ...
Source: Endpoints News